← Back to Treatments
🏅 FDA Orphan Designation

Banzel

rufinamide

Manufacturer: Eisai, Inc.

Indicated for:
Lennox-Gastaut syndromeOrphan

FDA-Approved Indications (1)

Lennox-Gastaut syndromeOrphan Designation

Adjunctive therapy of seizures associated with Lennox-Gastaut syndrome.

Indications & Usage

1 I NDICATIONS AND USAGE BANZEL is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome in pediatric patients 1 year of age and older and in adults. BANZEL is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in pediatric patients 1 year of age and older, and in adults ( 1 )

💙 Support Programs

View all →
Banzel
Eisai, Inc.

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.